Reporting from: – Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego – Chemotherapy Foundation Symposium, November 10-13 2004, New York – European So
Reporting from:
– Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego
– Chemotherapy Foundation Symposium, November 10-13 2004, New York
– European Society for Medical Oncology Congress, October 29-November 2, 2004, Vienna
– Journal of Clinical Oncology
– New England Journal of Medicine
In this edition:
At the ASH conference in San Diego, Owen O’Connor described his investigation involving heavily pretreated patients with mantle cell lymphoma whose disease responded to bortezomib. George Canellos discussed the clinical implications.
Rituximab-CHOP combination therapy markedly improved outcomes for low-risk, younger patients with diffuse large B-cell lymphoma, according to study results announced by Michael Pfreundschuh.
The oral 5-FU pro-drug capecitabine has performed as well as intravenous therapy, according to Chris Twelves, who presented findings to the Chemotherapy Foundation in New York.
The older drug hydroxyurea was just as effective and caused fewer complications than its molecularly targeted modern replacement, anagrelide, for treating patients with essential thrombocythemia, according to Tony Green,who spoke in San Diego.
Related Episodes
Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease
Charles E Geyer MD, at ESMO 2025, discusses DESTINY-Breast05 results, revealing trastuzumab deruxtecan (T-DXd) significantly improves disease-free survival for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. T-DXd outperformed trastuzumab emtansin
Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer
Some patients being treated for stage three colon cancer could avoid the use of chemotherapy and be spared toxicities such as neuropathy: according to a study in which ctDNA liquid biopsy monitoring f
Paul H Cottu MD PhD, ESMO Berlin: Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer
Aan identifyable subset of patients with high-risk ER+ HER2- early breast cancer better off without chemotherapy